CN108780091A - 用于检测和治疗卵巢癌的组合物和方法 - Google Patents

用于检测和治疗卵巢癌的组合物和方法 Download PDF

Info

Publication number: CN108780091A
Authority: CN; China
Prior art keywords: cdr; sequences; progastrin; antibody; amino acid
Prior art date: 2015-12-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201780013872.3A

Other languages

English (en)

Chinese (zh)

Inventor

A·普里厄

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pleij Goss Ryan Cancer Ltd

Progastrine et Cancers SARL

Original Assignee

Pleij Goss Ryan Cancer Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-31

Filing date

2017-01-02

Publication date

2018-11-09

2017-01-02 Application filed by Pleij Goss Ryan Cancer Ltd filed Critical Pleij Goss Ryan Cancer Ltd

2018-11-09 Publication of CN108780091A publication Critical patent/CN108780091A/zh

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 123
239000000203 mixture Substances 0.000 title claims abstract description 42
101800000285 Big gastrin Proteins 0.000 claims abstract description 227
RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 claims abstract description 217
206010033128 Ovarian cancer Diseases 0.000 claims abstract description 108
206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 107
238000011282 treatment Methods 0.000 claims abstract description 41
238000000338 in vitro Methods 0.000 claims abstract description 24
238000003745 diagnosis Methods 0.000 claims abstract description 23
230000002265 prevention Effects 0.000 claims abstract description 8
125000003275 alpha amino acid group Chemical group 0.000 claims description 111
239000012472 biological sample Substances 0.000 claims description 69
239000000523 sample Substances 0.000 claims description 58
239000000427 antigen Substances 0.000 claims description 40
108091007433 antigens Proteins 0.000 claims description 40
102000036639 antigens Human genes 0.000 claims description 40
239000012634 fragment Substances 0.000 claims description 36
210000004899 c-terminal region Anatomy 0.000 claims description 29
210000002381 plasma Anatomy 0.000 claims description 24
210000002966 serum Anatomy 0.000 claims description 12
239000013074 reference sample Substances 0.000 claims description 11
230000003472 neutralizing effect Effects 0.000 claims description 10
210000004369 blood Anatomy 0.000 claims description 7
239000008280 blood Substances 0.000 claims description 7
108090000623 proteins and genes Proteins 0.000 abstract description 17
102000004169 proteins and genes Human genes 0.000 abstract description 15
210000004027 cell Anatomy 0.000 description 73
235000001014 amino acid Nutrition 0.000 description 35
150000001413 amino acids Chemical class 0.000 description 35
206010028980 Neoplasm Diseases 0.000 description 31
241000282414 Homo sapiens Species 0.000 description 26
201000011510 cancer Diseases 0.000 description 25
239000000243 solution Substances 0.000 description 23
108090000765 processed proteins & peptides Proteins 0.000 description 17
125000000539 amino acid group Chemical group 0.000 description 16
235000018102 proteins Nutrition 0.000 description 14
239000000872 buffer Substances 0.000 description 13
238000002965 ELISA Methods 0.000 description 12
238000003556 assay Methods 0.000 description 12
229920001213 Polysorbate 20 Polymers 0.000 description 11
238000010790 dilution Methods 0.000 description 11
239000012895 dilution Substances 0.000 description 11
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 11
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 11
230000008685 targeting Effects 0.000 description 11
238000012360 testing method Methods 0.000 description 11
102400000921 Gastrin Human genes 0.000 description 10
238000002474 experimental method Methods 0.000 description 9
230000000903 blocking effect Effects 0.000 description 8
230000001394 metastastic effect Effects 0.000 description 8
206010061289 metastatic neoplasm Diseases 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
238000011534 incubation Methods 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
108060000903 Beta-catenin Proteins 0.000 description 6
102000015735 Beta-catenin Human genes 0.000 description 6
-1 CDR1-IMGT: 27 to 38 Proteins 0.000 description 6
108010052343 Gastrins Proteins 0.000 description 6
102000000763 Survivin Human genes 0.000 description 6
108010002687 Survivin Proteins 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
230000037361 pathway Effects 0.000 description 6
238000001262 western blot Methods 0.000 description 6
102400000948 Big gastrin Human genes 0.000 description 5
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
238000004020 luminiscence type Methods 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
210000000130 stem cell Anatomy 0.000 description 5
239000000758 substrate Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
239000011534 wash buffer Substances 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
NSORZJXKUQFEKL-JGVFFNPUSA-N Gln-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)N)N)C(=O)O NSORZJXKUQFEKL-JGVFFNPUSA-N 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
210000001124 body fluid Anatomy 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
238000001514 detection method Methods 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000003364 immunohistochemistry Methods 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
238000011002 quantification Methods 0.000 description 4
KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 3
101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 description 3
LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 3
XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 3
VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical group CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
RFEXGCASCQGGHZ-STQMWFEESA-N Phe-Gly-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O RFEXGCASCQGGHZ-STQMWFEESA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 3
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
108010068380 arginylarginine Proteins 0.000 description 3
108010047857 aspartylglycine Proteins 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
239000000090 biomarker Substances 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000013507 mapping Methods 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000012809 post-inoculation Methods 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
229950010131 puromycin Drugs 0.000 description 3
238000002626 targeted therapy Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
108010015666 tryptophyl-leucyl-glutamic acid Proteins 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 2
XPGVTUBABLRGHY-BIIVOSGPSA-N Asp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N XPGVTUBABLRGHY-BIIVOSGPSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
108010047041 Complementarity Determining Regions Proteins 0.000 description 2
241000938605 Crocodylia Species 0.000 description 2
IVCOYUURLWQDJQ-LPEHRKFASA-N Gln-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O IVCOYUURLWQDJQ-LPEHRKFASA-N 0.000 description 2
BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 2
LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 2
FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 2
GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
108010065920 Insulin Lispro Proteins 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 2
GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 2
GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 description 2
CYQQWUPHIZVCNY-GUBZILKMSA-N Pro-Arg-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CYQQWUPHIZVCNY-GUBZILKMSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
239000012083 RIPA buffer Substances 0.000 description 2
XPVIVVLLLOFBRH-XIRDDKMYSA-N Ser-Trp-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CO)C(O)=O XPVIVVLLLOFBRH-XIRDDKMYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
101150057615 Syn gene Proteins 0.000 description 2
WPSYJHFHZYJXMW-JSGCOSHPSA-N Trp-Gln-Gly Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O WPSYJHFHZYJXMW-JSGCOSHPSA-N 0.000 description 2
VPRHDRKAPYZMHL-SZMVWBNQSA-N Trp-Leu-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 VPRHDRKAPYZMHL-SZMVWBNQSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
HQYVQDRYODWONX-DCAQKATOSA-N Val-His-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N HQYVQDRYODWONX-DCAQKATOSA-N 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
238000009175 antibody therapy Methods 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
108010068265 aspartyltyrosine Proteins 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
238000000546 chi-square test Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
201000006549 dyspepsia Diseases 0.000 description 2
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
108010066264 gastrin 17 Proteins 0.000 description 2
GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 2
FMIHGWZLPSIAFY-WGFKALLTSA-N gastrin-34 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C1=CC=C(O)C=C1 FMIHGWZLPSIAFY-WGFKALLTSA-N 0.000 description 2
108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
108010017400 glycine-extended gastrin 17 Proteins 0.000 description 2
108010089804 glycyl-threonine Proteins 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
101150091368 mab-20 gene Proteins 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
238000002493 microarray Methods 0.000 description 2
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
239000013642 negative control Substances 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
230000007170 pathology Effects 0.000 description 2
229920001484 poly(alkylene) Polymers 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
238000002271 resection Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
229940126586 small molecule drug Drugs 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
238000012353 t test Methods 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
238000012762 unpaired Student’s t-test Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 description 1
JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 1
XEXJJJRVTFGWIC-FXQIFTODSA-N Ala-Asn-Arg Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XEXJJJRVTFGWIC-FXQIFTODSA-N 0.000 description 1
YSMPVONNIWLJML-FXQIFTODSA-N Ala-Asp-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(O)=O YSMPVONNIWLJML-FXQIFTODSA-N 0.000 description 1
CSAHOYQKNHGDHX-ACZMJKKPSA-N Ala-Gln-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CSAHOYQKNHGDHX-ACZMJKKPSA-N 0.000 description 1
YNOCMHZSWJMGBB-GCJQMDKQSA-N Ala-Thr-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O YNOCMHZSWJMGBB-GCJQMDKQSA-N 0.000 description 1
HCBKAOZYACJUEF-XQXXSGGOSA-N Ala-Thr-Gln Chemical compound N[C@@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O HCBKAOZYACJUEF-XQXXSGGOSA-N 0.000 description 1
PGNNQOJOEGFAOR-KWQFWETISA-N Ala-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 PGNNQOJOEGFAOR-KWQFWETISA-N 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
MUXONAMCEUBVGA-DCAQKATOSA-N Arg-Arg-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O MUXONAMCEUBVGA-DCAQKATOSA-N 0.000 description 1
CVKOQHYVDVYJSI-QTKMDUPCSA-N Arg-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCN=C(N)N)N)O CVKOQHYVDVYJSI-QTKMDUPCSA-N 0.000 description 1
OGZBJJLRKQZRHL-KJEVXHAQSA-N Arg-Thr-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OGZBJJLRKQZRHL-KJEVXHAQSA-N 0.000 description 1
DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 1
XBQSLMACWDXWLJ-GHCJXIJMSA-N Asp-Ala-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XBQSLMACWDXWLJ-GHCJXIJMSA-N 0.000 description 1
SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
HRVQDZOWMLFAOD-BIIVOSGPSA-N Asp-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)O HRVQDZOWMLFAOD-BIIVOSGPSA-N 0.000 description 1
CXEFNHOVIIDHFU-IHPCNDPISA-N Asp-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC(=O)O)N CXEFNHOVIIDHFU-IHPCNDPISA-N 0.000 description 1
PLNJUJGNLDSFOP-UWJYBYFXSA-N Asp-Tyr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PLNJUJGNLDSFOP-UWJYBYFXSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
102000008203 CTLA-4 Antigen Human genes 0.000 description 1
108010021064 CTLA-4 Antigen Proteins 0.000 description 1
229940045513 CTLA4 antagonist Drugs 0.000 description 1
101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
235000009091 Cordyline terminalis Nutrition 0.000 description 1
244000289527 Cordyline terminalis Species 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
230000000970 DNA cross-linking effect Effects 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229940123414 Folate antagonist Drugs 0.000 description 1
206010061968 Gastric neoplasm Diseases 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
LHMWTCWZARHLPV-CIUDSAMLSA-N Gln-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LHMWTCWZARHLPV-CIUDSAMLSA-N 0.000 description 1
SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 1
KBKGRMNVKPSQIF-XDTLVQLUSA-N Glu-Ala-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KBKGRMNVKPSQIF-XDTLVQLUSA-N 0.000 description 1
NEDQVOQDDBCRGG-UHFFFAOYSA-N Gly Gly Thr Tyr Chemical compound NCC(=O)NCC(=O)NC(C(O)C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 NEDQVOQDDBCRGG-UHFFFAOYSA-N 0.000 description 1
XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 1
IBYOLNARKHMLBG-WHOFXGATSA-N Gly-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IBYOLNARKHMLBG-WHOFXGATSA-N 0.000 description 1
WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
RJVZMGQMJOQIAX-GJZGRUSLSA-N Gly-Trp-Met Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(O)=O RJVZMGQMJOQIAX-GJZGRUSLSA-N 0.000 description 1
KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 1
DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 1
RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
UKTUOMWSJPXODT-GUDRVLHUSA-N Ile-Asn-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N UKTUOMWSJPXODT-GUDRVLHUSA-N 0.000 description 1
NCSIQAFSIPHVAN-IUKAMOBKSA-N Ile-Asn-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NCSIQAFSIPHVAN-IUKAMOBKSA-N 0.000 description 1
ZDNNDIJTUHQCAM-MXAVVETBSA-N Ile-Ser-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N ZDNNDIJTUHQCAM-MXAVVETBSA-N 0.000 description 1
PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 1
QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 1
JLYUZRKPDKHUTC-WDSOQIARSA-N Leu-Pro-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JLYUZRKPDKHUTC-WDSOQIARSA-N 0.000 description 1
XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 1
DTUZCYRNEJDKSR-NHCYSSNCSA-N Lys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN DTUZCYRNEJDKSR-NHCYSSNCSA-N 0.000 description 1
IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
LLGTYVHITPVGKR-RYUDHWBXSA-N Phe-Gln-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O LLGTYVHITPVGKR-RYUDHWBXSA-N 0.000 description 1
JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
OSBADCBXAMSPQD-YESZJQIVSA-N Phe-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N OSBADCBXAMSPQD-YESZJQIVSA-N 0.000 description 1
YFXXRYFWJFQAFW-JHYOHUSXSA-N Phe-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YFXXRYFWJFQAFW-JHYOHUSXSA-N 0.000 description 1
SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
XZONQWUEBAFQPO-HJGDQZAQSA-N Pro-Gln-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZONQWUEBAFQPO-HJGDQZAQSA-N 0.000 description 1
STASJMBVVHNWCG-IHRRRGAJSA-N Pro-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 STASJMBVVHNWCG-IHRRRGAJSA-N 0.000 description 1
VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 1
AWQGDZBKQTYNMN-IHRRRGAJSA-N Pro-Phe-Asp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)O)C(=O)O AWQGDZBKQTYNMN-IHRRRGAJSA-N 0.000 description 1
SPLBRAKYXGOFSO-UNQGMJICSA-N Pro-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2)O SPLBRAKYXGOFSO-UNQGMJICSA-N 0.000 description 1
RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
QKWYXRPICJEQAJ-KJEVXHAQSA-N Pro-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2)O QKWYXRPICJEQAJ-KJEVXHAQSA-N 0.000 description 1
229940079156 Proteasome inhibitor Drugs 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 1
DGHFNYXVIXNNMC-GUBZILKMSA-N Ser-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N DGHFNYXVIXNNMC-GUBZILKMSA-N 0.000 description 1
FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
IOVBCLGAJJXOHK-SRVKXCTJSA-N Ser-His-His Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IOVBCLGAJJXOHK-SRVKXCTJSA-N 0.000 description 1
ZUDXUJSYCCNZQJ-DCAQKATOSA-N Ser-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CO)N ZUDXUJSYCCNZQJ-DCAQKATOSA-N 0.000 description 1
NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 1
CRJZZXMAADSBBQ-SRVKXCTJSA-N Ser-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO CRJZZXMAADSBBQ-SRVKXCTJSA-N 0.000 description 1
HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 1
102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
241000282887 Suidae Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
XYEXCEPTALHNEV-RCWTZXSCSA-N Thr-Arg-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XYEXCEPTALHNEV-RCWTZXSCSA-N 0.000 description 1
TWLMXDWFVNEFFK-FJXKBIBVSA-N Thr-Arg-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O TWLMXDWFVNEFFK-FJXKBIBVSA-N 0.000 description 1
KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
UDNVOQMPQBEITB-MEYUZBJRSA-N Thr-His-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UDNVOQMPQBEITB-MEYUZBJRSA-N 0.000 description 1
KRGDDWVBBDLPSJ-CUJWVEQBSA-N Thr-His-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O KRGDDWVBBDLPSJ-CUJWVEQBSA-N 0.000 description 1
YUPVPKZBKCLFLT-QTKMDUPCSA-N Thr-His-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N)O YUPVPKZBKCLFLT-QTKMDUPCSA-N 0.000 description 1
238000010162 Tukey test Methods 0.000 description 1
ARSHSYUZHSIYKR-ACRUOGEOSA-N Tyr-His-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ARSHSYUZHSIYKR-ACRUOGEOSA-N 0.000 description 1
IQQYYFPCWKWUHW-YDHLFZDLSA-N Val-Asn-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N IQQYYFPCWKWUHW-YDHLFZDLSA-N 0.000 description 1
YMTOEGGOCHVGEH-IHRRRGAJSA-N Val-Lys-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O YMTOEGGOCHVGEH-IHRRRGAJSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
229960002833 aflibercept Drugs 0.000 description 1
108010081667 aflibercept Proteins 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
238000004630 atomic force microscopy Methods 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
238000000225 bioluminescence resonance energy transfer Methods 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229960005395 cetuximab Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000004154 complement system Effects 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
229960002465 dabrafenib Drugs 0.000 description 1
BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000002848 electrochemical method Methods 0.000 description 1
238000000572 ellipsometry Methods 0.000 description 1
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000000762 glandular Effects 0.000 description 1
108010078144 glutaminyl-glycine Proteins 0.000 description 1
108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
108010008671 glycyl-tryptophyl-methionine Proteins 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
230000012010 growth Effects 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000005305 interferometry Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229960005386 ipilimumab Drugs 0.000 description 1
108010057821 leucylproline Proteins 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
108010003700 lysyl aspartic acid Proteins 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000019569 negative regulation of cell differentiation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
229960001972 panitumumab Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
229960002621 pembrolizumab Drugs 0.000 description 1
229960002087 pertuzumab Drugs 0.000 description 1
238000002823 phage display Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
108010024607 phenylalanylalanine Proteins 0.000 description 1
108010051242 phenylalanylserine Proteins 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
230000010287 polarization Effects 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000035409 positive regulation of cell proliferation Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
108010077112 prolyl-proline Proteins 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000003207 proteasome inhibitor Substances 0.000 description 1
239000000649 purine antagonist Substances 0.000 description 1
239000003790 pyrimidine antagonist Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
108010048818 seryl-histidine Proteins 0.000 description 1
230000011664 signaling Effects 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
108010061238 threonyl-glycine Proteins 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000002834 transmittance Methods 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
108010037668 tyrosyl-glycyl-tryptophyl-methionyl-aspartyl-phenylalanyl-glycine Proteins 0.000 description 1
108010020532 tyrosyl-proline Proteins 0.000 description 1
108010003137 tyrosyltyrosine Proteins 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
108010015385 valyl-prolyl-proline Proteins 0.000 description 1
229960003862 vemurafenib Drugs 0.000 description 1
GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CN201780013872.3A 2015-12-31 2017-01-02 用于检测和治疗卵巢癌的组合物和方法 Pending CN108780091A (zh)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP15307192.3		2015-12-31
EP15307192		2015-12-31
EP16305138.6		2016-02-05
EP16305138		2016-02-05
PCT/EP2017/050033 WO2017114972A1 (en)	2015-12-31	2017-01-02	Compositions and methods for detecting and treating ovarian cancer

Publications (1)

Publication Number	Publication Date
CN108780091A true CN108780091A (zh)	2018-11-09

Family

ID=57821943

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201780013872.3A Pending CN108780091A (zh)	2015-12-31	2017-01-02	用于检测和治疗卵巢癌的组合物和方法

Country Status (13)

Country	Link
US (1)	US11760808B2 (ko)
EP (2)	EP3397964B1 (ko)
JP (2)	JP6962920B2 (ko)
KR (2)	KR102507685B1 (ko)
CN (1)	CN108780091A (ko)
AU (2)	AU2017204682B2 (ko)
BR (1)	BR112018013271A2 (ko)
CA (2)	CA3009751A1 (ko)
EA (1)	EA037015B1 (ko)
ES (1)	ES2901602T3 (ko)
PL (1)	PL3397964T3 (ko)
SG (1)	SG11201805605TA (ko)
WO (1)	WO2017114972A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3720879T (pt) *	2017-12-05	2022-07-13	Progastrine Et Cancers S A R L	Terapia de combinação entre anticorpo anti-progastrina e imunoterapia para tratar o cancro
KR102759239B1 (ko)	2017-12-08	2025-01-23	이씨에스-바이오트래커 에스에이알엘	암 진단에서 방사성표지된 프로가스트린
WO2019145537A1 (en)	2018-01-26	2019-08-01	Ecs-Progastrin Sa	Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
JP7485274B2 (ja)	2018-02-27	2024-05-16	イー、シー、エス、プロガストリン、エス、エー	免疫療法のためのバイオマーカーとしてのプロガストリン

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008076454A1 (en) *	2006-12-19	2008-06-26	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
US20110117086A1 (en) *	2009-10-16	2011-05-19	Bioréalités S.A.S.	Monoclonal antibodies to progastrin and their uses
WO2011083091A2 (en) *	2010-01-08	2011-07-14	Bioréalités S.A.S.	Methods for treating pancreatic cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8924581D0 (en)	1989-11-01	1989-12-20	Pa Consulting Services	Bleaching of hair
ATE356869T1 (de)	1990-01-12	2007-04-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
KR100654645B1 (ko)	1995-04-27	2007-04-04	아브게닉스, 인크.	면역화된 제노마우스 유래의 인간 항체
WO1996034096A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
EP2314625B1 (en)	1996-12-03	2014-05-07	Amgen Fremont Inc.	Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
DK0970126T3 (da)	1997-04-14	2001-08-13	Micromet Ag	Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
CA2580965C (en)	2004-09-22	2014-04-08	Receptor Biologix, Inc.	Monoclonal antibodies to progastrin
EP2156187A4 (en) *	2007-06-15	2010-07-21	Biosite Inc	METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND / OR PROGNOSIS OF OVARY CANCER AND LUNG CANCER
US9217032B2 (en)	2010-01-08	2015-12-22	Les Laboratoires Servier	Methods for treating colorectal cancer
US8900817B2 (en)	2010-01-08	2014-12-02	Les Laboratories Servier	Progastrin and liver pathologies
CN103003304B (zh) *	2010-03-24	2016-03-09	瑟维尔实验室	结直肠癌和胃肠癌的预防
US10533050B2 (en)	2010-07-26	2020-01-14	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods and compositions for liver cancer therapy

2017
- 2017-01-02 JP JP2018534923A patent/JP6962920B2/ja active Active
- 2017-01-02 BR BR112018013271A patent/BR112018013271A2/pt not_active IP Right Cessation
- 2017-01-02 SG SG11201805605TA patent/SG11201805605TA/en unknown
- 2017-01-02 EP EP17700480.1A patent/EP3397964B1/en active Active
- 2017-01-02 EP EP21199551.9A patent/EP3954999B1/en active Active
- 2017-01-02 PL PL17700480T patent/PL3397964T3/pl unknown
- 2017-01-02 CN CN201780013872.3A patent/CN108780091A/zh active Pending
- 2017-01-02 KR KR1020227022682A patent/KR102507685B1/ko active IP Right Grant
- 2017-01-02 ES ES17700480T patent/ES2901602T3/es active Active
- 2017-01-02 US US16/067,151 patent/US11760808B2/en active Active
- 2017-01-02 EA EA201891529A patent/EA037015B1/ru unknown
- 2017-01-02 CA CA3009751A patent/CA3009751A1/en active Pending
- 2017-01-02 CA CA3194356A patent/CA3194356A1/en active Pending
- 2017-01-02 KR KR1020187020588A patent/KR102428254B1/ko active IP Right Grant
- 2017-01-02 AU AU2017204682A patent/AU2017204682B2/en active Active
- 2017-01-02 WO PCT/EP2017/050033 patent/WO2017114972A1/en active Application Filing
2021
- 2021-10-11 AU AU2021250840A patent/AU2021250840B2/en active Active
- 2021-10-13 JP JP2021167961A patent/JP7279761B2/ja active Active

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008076454A1 (en) *	2006-12-19	2008-06-26	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
US20110117086A1 (en) *	2009-10-16	2011-05-19	Bioréalités S.A.S.	Monoclonal antibodies to progastrin and their uses
WO2011083091A2 (en) *	2010-01-08	2011-07-14	Bioréalités S.A.S.	Methods for treating pancreatic cancer
CN102892784A (zh) *	2010-01-08	2013-01-23	拜若提	用于治疗乳腺癌的方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AYAKO KIM等: "Therapeutic strategies in epithelial ovarian cancer", 《JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH》 *
HAYGOOD ET AL.: "Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?", 《WORLD J STEM CELLS》 *
WOUTER W. VAN SOLINGE等: "Ovarian Cancers Express and Process Progastrin", 《CANCER RESEARCH》 *
朱建伟等: "胃泌素与恶性肿瘤", 《普外临床》 *
闫竞一: "胃泌素、生长抑素与肿瘤细胞周期的调控", 《国外医学外科学分册》 *

Also Published As

Publication number	Publication date
CA3009751A1 (en)	2017-07-06
AU2021250840A1 (en)	2021-11-04
JP6962920B2 (ja)	2021-11-05
US20190002582A1 (en)	2019-01-03
KR102507685B1 (ko)	2023-03-08
SG11201805605TA (en)	2018-07-30
KR20180105647A (ko)	2018-09-28
EP3954999A1 (en)	2022-02-16
AU2017204682B2 (en)	2021-07-29
JP2022009080A (ja)	2022-01-14
EP3397964B1 (en)	2021-09-29
ES2901602T3 (es)	2022-03-23
EA037015B1 (ru)	2021-01-27
US11760808B2 (en)	2023-09-19
BR112018013271A2 (pt)	2018-12-11
WO2017114972A1 (en)	2017-07-06
PL3397964T3 (pl)	2022-02-07
KR20220100100A (ko)	2022-07-14
EP3954999B1 (en)	2025-01-15
EP3397964A1 (en)	2018-11-07
KR102428254B1 (ko)	2022-08-03
JP2019502923A (ja)	2019-01-31
AU2017204682A1 (en)	2018-07-19
AU2021250840B2 (en)	2024-06-27
EA201891529A1 (ru)	2019-01-31
CA3194356A1 (en)	2017-07-06
JP7279761B2 (ja)	2023-05-23

Publication	Publication Date	Title
US20240085423A1 (en)	2024-03-14	Compositions and methods for detecting and treating esophageal cancer
JP7478708B2 (ja)	2024-05-07	胃癌の検出および治療のための組成物および方法
AU2021250840B2 (en)	2024-06-27	Compositions and methods for detecting and treating ovarian cancer
US20240018264A1 (en)	2024-01-18	Compositions and methods for detecting and treating ovarian cancer

Legal Events

Date	Code	Title
2018-11-09	PB01	Publication
2018-11-09	PB01	Publication
2018-12-04	SE01	Entry into force of request for substantive examination
2018-12-04	SE01	Entry into force of request for substantive examination